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Mutations in the transcription factor methyl-CpG-binding-protein 2 (MeCP2) cause a
delayed-onset neurodevelopmental disorder known as Rett syndrome (RTT). Although
alteration in serotonin levels have been reported in RTT patients, the molecular
mechanisms underlying these defects are not well understood. Therefore, we chose to
investigate the serotonergic system in hippocampus and brainstem of male Mecp2−/y
knock-out mice in the B6.129P2(C)-Mecp2(tm1.1Bird) mouse model of RTT. The
serotonergic system in mouse is comprised of 16 genes, whose mRNA expression
profile was analyzed by quantitative RT-PCR. Mecp2−/y mice are an established
animal model for RTT displaying most of the cognitive and physical impairments
of human patients and the selected areas receive significant modulation through
serotonin. Using anatomically and functional characterized areas, we found region-
specific differential expression between wild type and Mecp2−/y mice at post-natal
day 40. In brainstem, we found five genes to be dysregulated, while in hippocampus,
two genes were dysregulated. The one gene dysregulated in both brain regions was
dopamine decarboxylase, but of special interest is the serotonin receptor 5b (5-ht5b),
which showed 75-fold dysregulation in brainstem of Mecp2−/y mice. This dysregulation
was not due to upregulation, but due to failure of down-regulation in Mecp2−/y mice
during development. Detailed analysis of 5-ht5b revealed a receptor that localizes to
endosomes and interacts with Gα i proteins.
Keywords: mouse models, 5-HT receptors, 5-ht5b receptor, Rett syndrome (RTT), MeCP2, serotonin
INTRODUCTION
Rett syndrome (RTT) is a progressive neurodevelopmental disorder caused by different mutations
in the X-chromosome-linked MECP2 gene (Amir et al., 1999). With an estimated prevalence of
1 in 10,000 live births (OMIM 312750, Rett, 1966), RTT is the second most common cause for
mental retardation in females after Down syndrome (Percy and Lane, 2004; Fehr et al., 2011)
and usually results from maternal or paternal de novo germline mutations (Thomas, 1996; Girard
et al., 2001), but is rarely transmitted through generations (Hoffbuhr et al., 2001). Affected children
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initially develop apparently normal, but after 6–18 months,
rapid developmental regression occurs where they lose previously
learned skills. Regression eventually halts, but is accompanied
by accelerated motor deterioration (Gillberg, 1986; Zappella,
1997). Characteristic features of RTT can be divided into mental
disabilities like cognitive impairment, loss of speech, anxiety
and seizures and bodily ailments. The latter can be grouped
into central dysfunctions like apraxia, ataxia and dystonia or
disturbed respiration and into autonomous dysfunctions like
constipation, oropharyngeal dysfunctions, cardiac abnormalities,
and osteopenia (Mount et al., 2001; Mari et al., 2005).
There are many different mouse models available that
resemble classical RTT (Ricceri et al., 2008). Although only
10% of all human mutations create a true null phenotype (Katz
et al., 2012), we chose the B6.129P2(C)-Mecp2(tm1.1Bird) mouse
model which shows a complete deletion of exons 3–4 (Guy et al.,
2001). A detailed comparison of all available models found little
differences between mouse lines regarding principle changes of
morphology, autonomic or motoric functions and lifespan or
neurological features, while the major differences were found in
cognition and behavior (Katz et al., 2012). However, substantial
differences in the time of onset and degree of severity between
different models have been reported (Chen et al., 2001; Guy et al.,
2001; Shahbazian et al., 2002).
The serotonergic system is one of the oldest neuro-modulatory
networks, and serotonergic dysfunction has been linked to similar
symptoms as listed above in other genetic disorders including
Prader–Willi or sudden infant death syndrome (Saito et al., 1999;
Weese-Mayer et al., 2003; Waters, 2010). Regarding RTT, some
groups reported reduced levels of serotonin in different brain
regions and in the cerebrospinal fluid both in human patients
as well as in Mecp2−/y mice (Jellinger, 2003; Ramaekers et al.,
2003). Projecting fibers from the raphé nuclei innervate basically
every brain region in mammals, although no alterations in the
raphé nuclei and its ascendant serotonergic fibers were observed
in Mecp2−/y mice at P21 and P56 (Santos et al., 2010). However,
until now there is no information about specific genes involved
in the serotonergic transmission in Mecp2−/y mice. With no
apparent alterations in the area of origin, we decided to compare
the regulation of the entire serotonergic system in two distinct
brain areas between healthy wild type mice and Mecp2−/y
littermates that receive considerable serotonergic projections.
Here, a single transmitter activates 13 different molecular targets,
12 being G-protein-coupled receptors (GPCRs) and one (5-
HT3R) is an ion channel. Adding to the count of 13 serotonergic
targets, 3 enzymes are associated with serotonin production or
transport. While RTT and related syndromes are so far incurable,
progress has been made with pharmacological treatment, targeted
at multiple GPCR populations in general (Wang et al., 2015)
and at the serotonergic system specifically. For example, the
application of 5-HT1A agonists was described to have beneficial
effects on the respiratory phenotype in mice (Abdala et al.,
2010), while pharmacological treatment with 5-HT7 agonists was
reported to improve behavior (De Filippis et al., 2014, 2015).
Considering the delayed onset of symptoms in RTT, we chose
to compare gene expression levels at P40 in male Mecp2−/y
knockout mice. Males at P40 displayed sufficiently developed,
uniform symptoms and were still healthy enough to collect
sufficient numbers for analysis. For this study we reasoned that
the complete lack of MeCP2 will better reveal any regulatory
effect than a highly variable Mecp2 expression in hemizygous
female mosaics.
MATERIALS AND METHODS
Ethics Statement
The experimental procedures were performed in accordance with
European Community (EU Directive 2010/63/EU for animal
experiments) and National Institutes of Health guidelines for
the care and use of laboratory animals. The study was approved
by the Georg-August-University, Göttingen and the approval ID
T12/18 was assigned to this work.
Nomenclature
Following with convention, we designated human genes with all
capital letters in italics (e.g., MeCP2), murine genes are given in
italics with a starting capital letter (e.g., Mecp2) and genotypes
are designated by superscript letters with “+” designating the
presence of the wild type allele, “−” designating the knock-out
of the allele and “y” indicating the male chromosome. Proteins
are given in capital letters not differentiating between human
and murine origin (e.g., MeCP2). For serotonin receptors, this
takes the form of 5-HTxR, with x designating the subtype. The
exception here are the members of serotonin receptor family 5,
whose members are given in the form 5-htxR.
Animals
The Mecp2 knockout mouse (Mecp2−/y), which is a model
for RTT, strain B6.129P2(C)-Mecp2tm1−1Bird (Guy et al., 2001)
maintained on a C57BL/6J background was obtained from The
Jackson Laboratory (Bar Harbor, ME, USA). Mecp2 knockout
males (Mecp2−/y) were generated by crossing hemizygous
Mecp2+/− females with C57BL/6J wild type males. Animals were
kept in a temperature- und humidity-controlled 12 h light-dark
cycle and had free access to water and standardized pellet food.
Genotyping
The genotype of newborn mice was determined using PCR on
DNA isolated from mice tail biopsies. Mice tails were incubated in
25 mM NaOH/0.2 mM EDTA for 3 h at 65◦C. After neutralization
with equal volume of 40 mM Tris/HCl pH 5.5, 1 µl was used as
template in a subsequent PCR. Primers for genotyping are given
in Table 1.
Quantitative RT-PCR
Gene expression was analyzed by quantitative RT-PCR analysis.
The total ribonucleic acid (RNA) of homogenized brain tissue
(hippocampus and brainstem) was isolated using the Trizol R©
method according to manufacturer’s instructions (GibcoBRL)
and its concentration was determined using the nanodrop ND-
1000 spectrophotometer followed by its quality and integrity
measurement by electrophoresis on RNA 6000 LabChip R© kit
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(Agilent 2100 Bioanalyzer). The RNA was transcribed into the
corresponding deoxyribonucleic acid (cDNA) using the iScript
cDNA Synthesis Kit (BioRad). The primer pairs (Table 1) were
designed by using the Primer3 program1.
Gel electrophoresis revealed a single polymerase chain
reaction (PCR) product, and the melting curve analysis showed
a single peak for all amplification products. The PCR products
were sequenced and blasted to confirm the correct identity of
each amplicon. Ten-fold serial dilutions generated from cDNA
of each sample were used as a reference for the standard
curve calculation to determine primer efficiency. Real-time PCR
reactions (25 µl) were performed in triplicates containing 1/20
volume of the sample cDNA preparation from 250 ng total RNA,
400 nM of each primers, and 1X iQ-SYBR Green Supermix
(BioRad, Laboratories, Ltd). The PCR-reactions were performed
as follows: initial denaturation at 98◦C for 30 s, 40 cycles of
(denaturation 94◦C/1 s, annealing 58◦C/15 s, extension 72◦C/1 s),
and a final gradual increase of 0.5◦C in temperature from
60◦C to 90◦C. All real-time quantifications were performed
using the iCycler iQ system (BioRad) and were adjusted by
using the method according to (Pfaﬄ, 2001). Hypoxanthine
guanine phosphoribosyl transferase (Hprt) served as reference
gene (“housekeeping gene”) for normalization in the qPCR.
Cell Culture, Transfection and Plasmids
Murine neuroblastoma cell line N1E-115 was obtained from the
American Type Culture collection (ATCC). Cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) containing 10%
fetal calf serum (FCS) and 1% penicillin/streptomycin at 37◦C
under 5% CO2.
For transient transfection, cells were seeded in cell
culture dishes and transfected with indicated plasmids using
Lipofectamine2000 Reagent (Invitrogen) according to the
manufacturer’s instruction.
Serotonin receptor 5b (5-ht5b) expression constructs were
generated from murine cDNA. Brain tissue was explanted and
used for total RNA isolation with the OLS RNA kit (OLS,
Germany) according to the manufacturer’s instructions. The
total RNA was used in one-step RT-PCR (Invitrogen) and
resulting PCR fragment was cloned into pTarget expression
vector (Promega). Primer sequences are given in Table 1. To
obtain a C-terminal fluorophore fusion construct of 5-ht5b, the
receptor and the fluorophores CFP, GFP, YFP or mCherry were
amplified individually, and fusion PCR was used to combine
the cDNAs. The resulting PCR fragment was cloned into
pTarget expression vector (Promega). To test the hypothesis
of a truncated 5-ht5b receptor, we amplified the unlabeled and
the mCherry fusion construct and cloned the fragments into
pTarget. Correct sequences of all constructs were determined by
sequencing.
The Gi3α-CFP plasmid was kindly provided by Dr. Andrew
Tinker (University College, London, UK). The Gsα-GFP plasmid
was a kind gift of Dr. Mark Rasenick (U. Illinois College of
Medicine, Chicago).
1http://frodo.wi.mit.edu/primer3/
Counterstaining of Intracellular
Compartments
The plasmids to fluorescently label the cell membrane (pYFP-
Mem), the endoplasmic reticulum (pYFP-ER), mitochondria
(pYFP-mito) and peroxisomes (pEGFP-Pex) were obtained from
Clontech. The plasmid to label the endosomes (GFP-Rab5;
Addgene plasmid # 31733) was a gift from Richard Pagano
(Choudhury et al., 2002). Lysosomes were counterstained with
LysoTracker (Thermo Scientific). The golgi apparatus was
counterstained using antibodies directed against cis golgi marker
GM-130 (sc-55591, Santa Cruz) and trans-golgi marker TGN38
(sc-166594, Santa Cruz).
Co-localization was observed using Zeiss LSM 510 Meta
system. Quantitative analysis of co-localization was carried out
by calculating Pearson’s correlation coefficients using LSM 510
software.
Immuno-Staining Procedures
Preparation of Tissue
To obtain tissue for immuno-fluorescence analysis, wild type
and Mecp2−/y mice (P40) were deeply anesthetized with
isoflurane (1-Chloro-2,2,2-trifluoroethyl-difluoro-methylether,
Abbott, Germany) until they were unresponsive to pain stimuli.
A thoracotomy was performed and animals were transcardially
perfused with 50 ml of 0.9% NaCl followed by 200 ml of 4%
phosphate-buffered formaldehyde (10 ml/min). The brain was
removed and post-fixed for 4 h with the same fixative at 4◦C.
Whole brains were stored in 1% formaldehyde in PBS at 4◦C.
Before sectioning, brains were equilibrated in HEPES buffer
(7.5 g NaCl, 0.3 g KCl, 0.06 g KH2PO4, 0.13 g Na2HPO4, 2 g
Glucose, 2.4 ml 10 mM HEPES, 0.1 g MgCl2, 0.05 g MgSO4,
0.165 g CaCl2, pH 7.4) for 48 h, cryoprotected in 15% sucrose
in PBS for 24 h followed by equilibration in 30% sucrose in
PBS for 24 h at 4◦C, and then frozen at −80◦C. Series of
30-µm-thick brain sections ranging from cervical spinal cord to
midbrain colliculi were cut using a freezing microtome (Frigocut,
Reichert-Jung, Germany). Sections were stored in HEPES buffer.
All buffers were supplemented with small amount sodium
azide.
Generation of Anti-5ht5b Antibodies
The polyclonal antibodies against the mouse 5-ht5b receptor
were generated by immunizing three New Zealand White
rabbits (Charles River) with a 15mer peptide representing
the C-terminus of the mouse 5-ht5b receptor amino acid
sequence (NP_034613.1; NH2-KNYNNAFKSLFTKQR-COOH).
For immunization purposes, peptides were coupled to keyhole
limpet hemocyanin (KLH). The rabbits were immunized with
300 µg KLH-coupled peptide in Hunter’s adjuvant (TiterMax
Gold, Sigma) five times (28-days-intervall). After estimation
of the antibody titer using enzyme-linked immune-sorbent
assay (ELISA) with solid phase-coated peptide, antibodies were
purified on an antigen-coupled CNBr-activated Sepharose R© 4B
column. The eluate was dialyzed against two changes of 5 l
PBS for 24 h at 4◦C, and finally concentrated to at least 1 µg
IgG/µl.
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TABLE 1 | List of primers used in this study for genotyping, cloning and quantitative RT-PCR.
Genotyping Mecp2−/y WT for GACCCCTTGGGACTGAAGTT NM_010788.3
rev CCACCCTCCAGTTTGGTTTA
Mecp2−/y KO for CCATGCGATAAGCTTGATGA
rev CCACCCTCCAGTTTGGTTTA
Cloning Htr5b full length for ATGGAAGTTTCTAACCTCTC NM_010483.3
rev TTATCTCTGCTTAGTAAAGAG
Htr5b trunc for ATGATCGCGATCACCTGGG
rev TTATCTCTGCTTAGTAAAGAG
RT-qPCR Htr1a for AACTATCTCATCGGCTCCTT NM_008308.4
rev GATTGCCCAGTACCTGTCTA
Htr1b for CTCCATCTCTATTTCGTTGC NM_010482.1
rev GTCTTGTTGGGTGTCTGTTT
Htr1d for CCATCCATCTTGCTCATTAT NM_008309.4
rev CACCTGGTTGAAAAAGAGAG
Htr1f for TTTCTACATCCCGCTTGTAT NM_008310.3
rev TCGGACAAGGATTTTTCTAA
Htr2a for TGTGATGCTTTTAACATTGC NM_172812.2
rev CCAACTTACTCCCATGCTAC
Htr2b for GAACATCCTTGTGATTCTGG NM_008311.2
rev AGGCAGTTGAAAAGAGAACA
Htr2c for CTATTTTCAACTGCGTCCAT NM_008312.4
rev ATTCACGAACACTTTGCTTT
Htr3a for TGGTCCTAGACAGAATAGCC NM_013561.2
rev GGTCTTCTCCAAGTCCTGA
Htr4 for CCTCACAGCAACTTCTCCTT NM_008313.4
rev TCCCCTGACTTCCTCAAATA
Htr5a for TGCTCTTTGTGTACTGGAAA NM_008314.2
rev ACGTATCCCCTTCTGTCTG
Htr5b for GAGTCTGAGATGGTGTTCA NM_010483.3
rev AATATCCAAGCCACAGGAAT
Htr6 for CTGAGCATGTTCTTTGTCAC NM_021358.2
rev CATGAAGAGGGGATAGATGA
Htr7 for GTTAGTGTCACGGACCTCAT NM_008315.2
rev ATCATTTTGGCCATACATTT
Slc6a4 for AAGCCAAGCTGATGATGTAA NM_010484.2
rev TCCTCACATATCCCAGTCAG
Ddc for GCAGTGCCTTTATCTGTCCT NM_001190448.1
rev GAATCCTGAGTCCTGGTGAC
Tph2 for CAGGGTCGAGTACACAGAAG NM_173391.3
rev CTTTCAGAAACATGGAGACG
Hprt for ATTAGCGATGATGAACCAGG NM_013556.2
rev GTCAGCAAAGAACTTATAGCCC
Gapdh for CAAGCTCATTTCCTGGTATGAC NM_008084.1
rev AGGCCCCTCCTGTTATTATG
Accession numbers are given for the murine gene used to generate the primers. If there were multiple transcript variants of a gene, our primers were designed to be
specific for the main transcript and did not discriminate between transcript variants.
Immuno-Fluorescence Microscopy
Immuno-fluorescence analysis was started with antigen retrieval
using citrate buffer (10 mM citric acid, 0.05% Tween20, pH 6.0) at
80◦C for 30 min. Sections were incubated in blocking buffer (PBS,
0.1% Triton-X100, 1% Tryptone/Peptone) for 60 min at RT to
permeabilize and block non-specific binding. Primary antibody
(rabbit anti-5ht5b) was diluted 1:100 in blocking buffer and
incubated for 60 min at RT. After washing in washing buffer (PBS,
0.05% Tween20, 0.3% Triton X100), sections were incubated
for 1 h at RT in the dark with anti-rabbit atto647-conjugated
secondary antibodies (Sigma–Aldrich, Cat. No. 40839) diluted
1:400 in blocking buffer. Sections were counterstained with
DAPI during the wash step, then mounted onto microscope-
slides and cover-slipped with Mowiol. Immuno-fluorescence was
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analyzed with a Zeiss fluorescence microscope (Zeiss, Germany).
Images were taken at 10x magnification and were imported into
ImageJ (Schneider et al., 2012), digitally adjusted if necessary for
brightness and contrast, and assembled into plates. All buffers
were supplemented with small amount sodium azide.
Immunoelectron Microscopy
Immunoelectron microscopy of ultrathin cryosections was
performed as described previously (Feldmann et al., 2011). In
brief, WT and MeCP2-deficient mice were anesthetized with
isoflurane and transcardially perfused with 4% formaldehyde
(Serva) in 0.1 M phosphate buffer. Vibratome sections of the
brain stem were infiltrated with 2.3 M sucrose in 0.1 M phosphate
buffer overnight. Small blocks from the region of the brainstem
were mounted onto aluminum pins for ultramicrotomy and
frozen in liquid nitrogen. Ultrathin cryosections were immune-
labeled with rabbit antibodies specific for 5-ht5b receptor and
protein A-gold (10 nm) obtained from the Cell Microscopy
Center, Department of Cell Biology, University Medical Center
Utrecht, The Netherlands. Sections were analyzed with a LEO
EM912AB (Zeiss, Oberkochen) and digital micrographs were
obtained with an on-axis 2,048 × 2,048-CCD camera (TRS,
Moorenweis).
Western Blotting of the 5-ht5b Receptor
Brain tissue from Mecp2−/y mice or N1E-115 cells transfected
with expression plasmids encoding the full-length murine
5-ht5b receptor were resuspended in 300 µl Laemmli buffer
[20 mM Tris/HCl, pH 6.8, 2 mM EDTA, 2% (w/v) SDS, 10%
(v/v) 2-mercaptoethanol, 10% (v/v) glycerol and 0.3% (w/v)
bromophenol blue] supplemented with a protease inhibitor
cocktail (Sigma) and boiled for 5 min at 95◦C. Proteins (50 µg
of each sample) were separated using 10% SDS–PAGE and
transferred onto a nitrocellulose membrane. The membrane was
blocked with 2% w/v BSA/TBS (pH 7.4) for 30 min at RT
and antigen was detected using a primary polyclonal antibody
(1:1,000 dilution) for 120 min at RT. Secondary antibodies
(IRDye 800CW-conjugated anti-rabbit, LI-COR, Lincoln, NE,
USA) were used at a dilution of 1:10,000 for 2 h at RT. The
visualization of the antigen–antibody reaction was performed
using the Odyssey detection system (LI-COR). To test specificity,
the anti-5-ht5b receptor antibody was pre-incubated with a 50-
fold molar excess of the immunizing peptide, which led to the
vanishing of the specific 22.5 kDa band.
Assay for [35S]GTPγS Binding and
Immune-Precipitation of G Protein α
Subunits
Membrane preparations of transiently transfected mouse N1E-
115 neuroblastoma cells expressing the full-length or truncated
5-ht5b receptor linked to cherry fluorophore and G-protein α
subunits (Gαi3 and Gαs fused to variants of green fluorescent
protein) were performed according to the protocol described by
Kvachnina et al. (2009). Membrane preparations were diluted in
reaction buffer (50 mM Tris/HCl pH 7.4, 2 mM EDTA, 100 mM
NaCl, 3 mM MgCl2, and 1 µM GDP) to a concentration of
1 µg/µl. Each reaction contained 50 µg membranes in a total
volume of 100 µl. Reactions were performed in triplicate. After
adding [35S]GTPγS (Hartmann Analytic) to a final concentration
of 3 nM, samples were incubated for 5 min at 30◦C in the
presence or absence of 1 µM 5-HT. The reaction was terminated
by adding 900 µl of RIPA-buffer (20 mM Tris/HCl pH 7.4, 0.15
M NaCl, 10 mM EDTA, 10 mM Iodacetamide, 1% Triton X-
100, 1% sodium deoxycholate and 0.1% SDS) for 30 min on
ice. Samples were centrifuged at 13,000 rpm for 10 min. The
supernatants were transferred into a new tube and samples were
incubated for 2 h after addition of 100 µl protein A-Sepharose
(Sigma, 20 mg/ml RIPA) and 0.5 µl of goat anti-GFP antibodies
(University of Alberta, TEC Edmonton). Immuno-precipitates
were washed three times, boiled in 0.5 ml of 0.5% SDS, and
radioactivity was measured by scintillation counting.
Statistical Analysis
Statistical significance of the data was tested by non-parametric
Mann–Whiney test using GraphPad Prism 5 (GraphPad Software
Inc., La Jolla, CA, USA) on a Microsoft Windows PC. P-value
less than 0.05 is considered significant. Data are presented as
mean± standard error of the mean (SEM).
RESULTS
The Serotonergic System
We used quantitative RT-PCR to analyze the complete
serotonergic system in hippocampus and brainstem of WT
and Mecp2−/y mice on the transcriptional level. We analyzed
a total of 16 genes that included the serotonin receptors Htr1a,
Htr1b, Htr1d, Htr1f, Htr2a, Htr2b, Htr2c, Htr3a, Htr4, Htr5a,
Htr5b, Htr6, Htr7, the serotonin transporter (Slc6a4), and
the synthesizing enzymes dopamine decarboxylase (Ddc) and
tryptophan hydroxylase 2 (Tph2). The serotonin receptor Htr1e
was not analyzed as it is absent in mice. Also note that Htr1c
is not listed above. The gene was, after its initial discovery and
characterization, renamed to Htr2c (OMIM 312861). Table 1 lists
the accession numbers of the murine genes of the serotonergic
system and the sequences of the primers used for RT-qPCR.
Analyses were performed at postnatal day 40 (P40), a stage
where Mecp2−/y mice have already developed a RTT phenotype
with hind limb clasping, low body weight and several other of
the mentioned symptoms (Stettner et al., 2008). All differentially
expressed genes are summarized in Table 2.
TABLE 2 | Dysregulated genes of the serotonergic system in brainstem
and hippocampus at P40.
Hippocampus Brainstem
Htr1d – ↑ (∗∗)
Htr2c – ↓ (∗∗)
Htr5b – ↑ (∗∗)
Ddc ↑ (∗∗) ↑ (∗∗∗)
Slc6a4 ↓ (∗∗∗) –
Tph2 – ↓ (∗∗)
Asterisks indicate significance (∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001).
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FIGURE 1 | Comparison of mRNA expression of the serotonergic system in WT vs. Mecp2−/y mice in the brainstem at P40. Messenger RNA level in the
brainstem was measured by qPCR for WT (black) and Mecp2−/y (red) mice at postnatal day 40. (A) Htr1a, (B) Htr1b, (C) Htr1d, (D) Htr1f, (E) Htr2a, (F) Htr2b, (G)
Htr2c, (H) Htr3a, (I) Htr4, (J) Htr5a, (K) Htr5b, (L) Htr6, (M) Htr7, (N) Slc6a4, (O) Ddc, and (P) Tph2. The bar diagrams represent the results of separate qPCR
analyses with mean values and standard error of the mean from n = 5 biological replicates of genes for the serotonin receptors Htr1a, Htr1b, Htr1d, Htr1f, Htr2a,
Htr2b, Htr2c, Htr3a, Htr4, Htr5a, Htr5b, Htr6, Htr7, the serotonin transporter (Slc6a4), and the enzymes dopamine decarboxylase (Ddc) and tryptophan hydroxylase
2 (Tph2). The y-axis shows relative expression. Asterisks indicate significance (∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001).
Regulation of Components of the
Serotonergic System in the Brainstem
The differential expression levels for all 16 components of
the murine serotonergic system in the brainstem are given
in Figure 1, where the WT was set to 1. In the brainstem,
5 of the 16 genes of the murine serotonergic system were
dysregulated between WT and Mecp2−/y mice at P40. These
were the three serotonin receptor genes Htr1d, Htr2c and
Htr5b, as well as the non-receptor genes Ddc and Tph2. Also,
Htr4 and Htr6 showed strong, although not yet significant
dysregulation.
The mRNA level for Htr1d in Mecp2−/y mice showed a
2-fold up-regulation (Figure 1C; 2.29 ± 0.184, p = 0.0013).
Htr1d affects locomotion and anxiety and also induces vascular
vasoconstriction in the brain. In addition, 5-HT1DR has been
implicated in controlling activity of raphé neurons and therefore
serotonin release. An up-regulation of 5-HT1DR in the brainstem
could therefore inhibit the serotonin release in the raphé
nuclei and thus explain the low brain serotonin levels reported
previously (Mokler et al., 1998).
The mRNA level of Htr2c was reduced to roughly half
compared with WT (Figure 1G; 0.482± 0.057; p= 0.005). Htr2c
activation inhibits dopamine and norepinephrine release in the
striatum, prefrontal cortex, nucleus accumbens, hippocampus,
hypothalamus, and amygdala among other areas (Alex et al.,
2005). It also regulates mood, anxiety, feeding, and reproductive
behavior (Heisler et al., 2007). In the brainstem, Htr2c is
associated with respiratory dysfunction (Tecott et al., 1995;
Hodges et al., 2009).
The most striking difference was observed for Htr5b with
an up-regulation in Mecp2−/y mice by a factor of 75 at P40
compared to age-matched WT mice (Figure 1K; 76.43 ± 15.86;
p = 0.0089). Htr5b showed a tremendous dysregulation with
nearly 75-fold upregulation in Mecp2−/y mice. Unfortunately,
little is known about this specific serotonin receptor. Based on
molecular studies, Htr5b is grouped with Htr5a forming the fifth
class of serotonin receptors. The two 5-ht5 receptors are the only
serotonin receptors that are transcribed from two exons (Matthes
et al., 1993). Htr5b is believed to be non-functional in humans
because its coding sequence is interrupted by several stop codons
and repeated insertions (Grailhe et al., 2001), while rodents carry
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a fully intact Htr5b gene. Therefore, we performed some basic
tests to determine the relevance of Htr5b dysregulation in RTT
(see below).
Tryptophan hydroxylase 2 (Tph2) was reduced 2-fold in
Mecp2−/y mice compared to WT (Figure 1P; 0.553 ± 0.379,
p= 0.0067). Tph2 is the main synthesizing enzyme for serotonin,
hydroxylating the rate-limiting step from L-tryptophan to
5-hydroxy-L-tryptophan (Kuhar et al., 1999). Tph2 is mainly
expressed in neurons of the raphé nuclei, which contain the
majority of serotonin-containing neurons (Frazer and Hensler,
1999). A defect of Tph2 could explain reduced levels of serotonin
in the brain and in the cerebrospinal fluid (Jellinger, 2003;
Ramaekers et al., 2003). The dopamine decarboxylase (Ddc) level
was increased 3-fold in Mecp2−/y mice (Figure 1O; 3.48± 0.299,
p< 0.001).
Regulation of Components of the
Serotonergic System in Hippocampus
The differential expression levels for all 16 components of the
murine serotonergic system in the hippocampus are given in
Figure 2, where the WT was set to 1. In hippocampus, of the
16 genes of the serotonergic system, only two showed differential
expression between WT and Mecp2−/y mice.
Ddc, which was upregulated threefold in the brainstem,
was also up-regulated twofold in hippocampus (Figure 2O;
2.459 ± 0.336, p = 0.0015). Ddc catalyzes several different
decarboxylation reactions (Siegel et al., 1999), thus mutations
in Ddc lead to reduced levels of neurotransmitters dopamine
and serotonin (Ramaekers et al., 2003). However, neither for
dopamine nor for serotonin synthesis, Ddc is the rate-limiting
enzyme (Kuhar et al., 1999), whereas in humans Ddc is the rate-
limiting enzyme for the synthesis of trace amine transmitter
(Berry, 2004). For the serotonergic system, Ddc catalyzes the
decarboxylation of 5-Hydroxy-L-Tryptophan to serotonin, while
Ddc also catalyzes the conversion of 3,4-dihydroxyphenylalanine
(DOPA) and Levodopa to dopamine. Dopamine in the basal
ganglia is important for coordination and smooth movement,
and Mecp2−/y mice show disturbed motor function like hind
limb clasping.
The second dysregulated gene in hippocampus was Slc6a4)
which was down-regulated in Mecp2−/y mice (Figure 2N;
0.387 ± 0.611, p < 0.001). Slc6a4 (solute carrier family 6
member 4) encodes the serotonin transporter SERT (Blakely
et al., 1991; Hoffman et al., 1991) and removes serotonin from
the synaptic cleft, thus terminating its action by transporting 5-
HT into the presynaptic neuron in a sodium-dependent manner
(Horschia, 2001). Mutations in the Slc6a4 promoter affect the
rate of serotonin uptake (Caspi et al., 2003) and are therefore
associated with numerous diseases like sudden infant death
syndrome (Weese-Mayer et al., 2003), and propensity to post-
traumatic stress disorder (Liu et al., 2015) or susceptibility for
depression (Lin et al., 2015).
An up-regulation of Ddc in RTT would have little effect
on the availability and therefore on the strength of synaptic
transmission. However, a down-regulation of Slc6a4 in
RTT would result in increased serotonin-mediated synaptic
transmission due to longer dwell time of 5-HT in the synaptic
cleft. Therefore, and because no other genes were found
dysregulated in hippocampus, we believe that upregulation of
Ddc and down-regulation of Slc6a4 could be an adaption to low
serotonin levels reported previously (Ramaekers et al., 2003).
Differences between Brainstem and
Hippocampus
In our mouse model of RTT syndrome, 6 out of 16 genes
constituting the serotonergic system in mouse were differentially
regulated. Of these six genes, only two genes were dysregulated
in hippocampus and only dopamine decarboxylase (Ddc) was
dysregulated in both brain regions. Ddc was up-regulated in
Mecp2−/y mice in hippocampus and brainstem by approximate
the same factor, which might suggests a genetic reason for
the up-regulation, e.g., the missing of transcriptional inhibitor
Mecp2. Nevertheless, in hippocampus, up-regulation of Ddc
might compensate for the down-regulation of Slc6a4 or vice
versa. There have been reports of reduced serotonin (Jellinger,
2003; Ramaekers et al., 2003) and dopamine (Riederer et al.,
1986; Lekman et al., 1989; Wenk et al., 1991) levels in the brain
and cerebrospinal fluid of RTT patients which are compensated
by increased expression of dopamine receptor (Chiron et al.,
1993). The decrease of both neurotransmitters make it like that
the dysregulation of both Ddc and Slc6a4 in hippocampus is
compensatory.
Profiling Developmental Changes of
Htr5b
After identifying Htr5b to be profoundly dysregulated in the
brainstem at P40, we profiled the expression of this gene during
the development at P7, P14, P21, P40, and P50 (Figure 3A).
Up until P21, Htr5b expression increases uniformly in WT and
Mecp2−/y mice. After reaching peak expression around P21,
Htr5b expression in WT mice is essentially turned off after P21.
However, inMecp2−/y mice it remains at the same elevated levels.
Thus, the observed dysregulation is not due to an upregulation of
Htr5b in Mecp2−/y mice, but due to a failure to down-regulate
Htr5b expression. In hemizygous female mice at P75, we also
found a significant dysregulation, albeit not as strong as in male
knockout mice (Figure 3B). However, female mice at this age
do not display the same advanced disease progression as male
mice and they are mosaics, displaying varying gene expression
patterns. Considering the identical profiles in WT and Mecp2−/y
mice up to P21, one can speculate that Htr5b expression
may serve a physiological purpose in mice. The intracellular
localization of 5-ht5b and the nearly complete down-regulation
after P21 indicates that 5-ht5b might act more like a regulator
than a receptor. In addition to Htr5b, we also assayed the other
genes found dysregulated in P40 male mice again in P75 female
mice (Figures 3C,D). All genes showed a comparable trend in the
female mice as found in the male mice, although the differences
between WT and Mecp2+/− animals were much smaller. In
brainstem (Figure 3C), Htr2c (0.672 ± 0.124, p = 0.012) and
Ddc (1.841 ± 0.198, p = 0.026) were found to be significantly
dysregulated. In hippocampus (Figure 3D), only Ddc showed
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FIGURE 2 | Comparison of mRNA expression of the serotonergic system in WT vs. Mecp2−/y mice in the hippocampus at P40. Messenger RNA level in
the hippocampus was measured by qPCR for WT (black) and Mecp2−/y (red) mice at postnatal day 40. (A) Htr1a, (B) Htr1b, (C) Htr1d, (D) Htr1f, (E) Htr2a, (F)
Htr2b, (G) Htr2c, (H) Htr3a, (I) Htr4, (J) Htr5a, (K) Htr5b, (L) Htr6, (M) Htr7, (N) Slc6a4, (O) Ddc, and (P) Tph2. The bar diagrams represent the results of separate
qPCR analyses with mean values and standard error of the mean from n = 5 biological replicates of genes for the serotonin receptors Htr1a, Htr1b, Htr1d, Htr1f,
Htr2a, Htr2b, Htr2c, Htr3a, Htr4, Htr5a, Htr5b, Htr6, Htr7, the serotonin transporter (Slc6a4), and the enzymes dopamine decarboxylase (Ddc) and tryptophan
hydroxylase 2 (Tph2). The y-axis shows relative expression. Asterisks indicate significance (∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001).
a significant dysregulation (1.452 ± 0.1, p = 0.0286). The
lower number of significantly dysregulated genes as well as
the smaller differences between WT and Mecp2+/− females
could be explained in two ways. Hemizygous mice are a mosaic
regarding Mecp2 activity, thus generating greater variability of
gene regulation. Also, females develop symptoms much later, so
possible differences may not be detectable at P75.
Molecular Analysis of Serotonin
Receptor 5b (5-ht5b)
The tremendous dysregulation of Htr5b and lack of previous
research prompted us to analyze this receptor in more detail at
the protein level.
If any, only weak 5-ht5b receptor expression was found in
the hippocampus of both WT and Mecp2−/y mice at P40 (data
not shown). The same was true for the brainstem of WT mice
(Figures 4A,C), while in MeCP2-deficient mice, 5-ht5b receptors
were found in abundance (Figures 4B,D). Thus, receptor
staining was in agreement with our qPCR expression data.
Closer inspection of the immune-histochemical data revealed an
unusual staining pattern for 5-ht5b with punctate intracellular
pattern instead of uniform labeling of the cytoplasm (Figure 4E).
Interestingly, transfection of a 5ht5b-fluorescent protein fusion
construct in neuroblastoma cells produced the same intracellular
expression pattern (Figure 4F).
Western blot analyses of both brainstem tissue (Figure 5B,
IV) and neuroblastoma cells transfected with Htr5b (Figure 5B,
II) verified the presence of a protein of approximately 40 kDa,
as expected from the genetic sequence. In addition, western
blots of transfected cells and murine tissue revealed a signal
at 22.5 kDa (Figure 5B, II, IV). Such a signal is also obtained
when a truncated 5-ht5b is transfected (Figure 5, III). The
truncated receptor of 22.5 kDa might be important for Htr5b
expression in humans. The human Htr5b gene is considered
to be a pseudo-gene, as its first exon is disrupted by several
mutations (Grailhe et al., 2001). However, sequence comparison
between different species indicated the presence of a highly
conserved second start codon surrounded by a classic Kozak
sequence (Grailhe et al., 2001) in Htr5b. Transcription starting
from this second exon would result in a shortened protein
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FIGURE 3 | Developmental profile of Htr5b in brainstem of WT and Mecp2-deficient mice. (A) Shown are the messenger RNA levels of Htr5b at post-natal
days P7, P14, P21, P40, and P50 for male WT (black) and Mecp2−/y (red) mice. Htr5b expression increases in parallel in WT and Mecp2−/y until P21, after which it
is downregulated completely in WT, but remains at the previously seen level in Mecp2−/y mice until P50, indicating a failure of down-regulation. (B) Messenger RNA
levels of Htr5b at post-natal day P75 in female WT and Mecp2+/− mice. Htr5b also displays a significant dysregulation at P75 in female mice, although the
dysregulation is by far not as pronounced as in male mice. Analyses were performed in triplicates with at least 3 different animals. (C) Messenger RNA levels of
Htr1d, Htr2c, Ddc and Tph2 in brainstem at post-natal day P75 in female WT and Mecp2+/− mice. Htr1d, Htr2c, and Ddc in brainstem show a significant
dysregulation. (D) Messenger RNA levels of Ddc and Slc6a4 in hippocampus at post-natal day P75 in female WT and Mecp2+/− mice. Analyses were performed in
triplicates with at least 3 different animals. The y-axis shows relative expression. Asterisks indicate significance (∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001).
with a predicted molecular mass of 22.5 kDa. An artificially
truncated murine 5-ht5b receptor behaved nearly identical to
the full length version (data not shown), leaving the possibility
that a truncated 5-ht5b might also be present in humans and
contributes to RTT. Incidentally, two immune-reactive bands
were also reported for 5-ht5a (Dutton et al., 2008). As both class
5 serotonin receptors are transcribed from two exons (Matthes
et al., 1993), the presence of two protein variants might be a
class-defining feature.
N1E-115 neuroblastoma cells expressing fluorescent 5-ht5b
were either co-transfected with or counter-stained against
specific organelle markers to determine 5-ht5b’s intracellular
compartment. As expected, some co-localization was seen with
the ER (Figure 6A, correlation coefficient 0.539 ± 0.08) and
cis-golgi marker GM130 (Figure 6B, 0.584 ± 0.05) as proteins
are produced here and are sorted for trafficking to the membrane.
However, no receptor reached the plasma membrane (Figure 6C,
0.086 ± 0.01). Strong co-localization of 5-ht5b receptors was
seen with endosomal compartments, shown exemplarily for
early endosome marker rab5 (Figure 6D, 0.873 ± 0.02). No
co-localization of 5-ht5b receptors was detected with markers for
trans-golgi marker TGN38 (Figure 6E, 0.094 ± 0.03) or with
lysosomes (Figure 6F 0.359 ± 0.04), meaning that the receptor
is neither trafficked to the membrane nor sent immediately for
degradation. For completeness, we also checked mitochondria
(Figure 6G, 0.359 ± 0.04) and peroxisomes (Figure 6H,
0.343± 0.06), but found no co-localization with 5-ht5b.
An immune-gold electron microscopic analysis from mouse
brainstem revealed that 5-ht5b receptors seemed integrated in
vesicular organelles (Figures 7A,B), consistent with the light
microscopic images (Figures 6A–H). The G-protein binding
domain of a receptor integrated into organelles would be
accessible from the cytoplasm (Figure 7C). To determine
whether 5-ht5b, which has lost its capability to be expressed
at the plasma membrane, can still serve its function as a
receptor and interact with G-proteins, we studied the signaling
pathway of the full-length 5-ht5b receptor in neuroblastoma
cells by co-expressing Gαi or Gαs protein subunits. A GTPγS-
assay revealed that cells co-expressing 5-ht5b receptors and
Gαi proteins exhibited a 220% increase of the baseline
signal. Cells co-expressing 5-ht5b receptor and Gαs as well
as the mock-transfected control did not show any significant
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FIGURE 4 | Distribution and upregulation of 5-ht5b in brainstem of Mecp2−/y mice. Representative immunohistological stainings of one out of three animals
analyzed each. (A) In WT mice, 5-ht5b-receptor-positive cells (red) were virtually undetectable at postnatal day 40 (P40). (B) In contrast, mice with MeCP2 deficiency
(Mecp2−/y ) displayed a marked increase in the number of 5-ht5b-receptor immuno-reactive cells. (C,D) Higher magnification images of areas indicated in (A,B).
(E) High magnification images of 5-ht5b-receptor-positive cells (red) revealed a clustered intracellular distribution indicating organelle localization of receptors. (F) The
same clustered intracellular distribution was found when full length Htr5b fused to mCherry was expressed in murine neuroblastoma cell line N1E-115. Nuclei are
counterstained with DAPI (blue). NTS, nucleus of the solitary tract; Rob, raphe obscurus nucleus; Sp5C, spinal trigeminal nucleus, caudal part; VLM, ventrolateral
medulla; XII, hypoglossal nucleus. Scale bars as indicated.
changes. The expression of Gαi alone resulted in a minor
increase of 39% (Figure 7D). Overexpression of fluorescently
labeled Gαi protein led to a faint membrane translocation of
otherwise strictly intracellular 5-ht5b, indicating protein–protein
interaction (Figure 7D). Although we found no cell surface
expression using recombinant fusion constructs (Figures 6A–H),
we need to note that early investigations found a reaction of 5-
ht5b to stimulation by serotonin in rodents (Matthes et al., 1993),
thus a small amount of receptor may reach the cell surface.
DISCUSSION
The RTT is characterized by cognitive impairment, anxiety,
oropharyngeal dysfunctions, cardiac abnormalities, osteopenia,
impaired locomotor skills, propensity for seizure and disturbed
breathing (Lugaresi et al., 1985; Gillberg, 1986; Glaze et al.,
1987; Elian and Rudolf, 1991; Zappella, 1997; Mount et al., 2001;
Steffenburg et al., 2001). Most of these symptoms are also present
in the Mecp2 knock-out (Mecp2−/y) mouse model used here
(Guy et al., 2001).
In any animal model of RTT, the choice between heterozygous
males or hemizygous females has advantages and disadvantages.
Heterozygous females are favored by many, as they might
more closely resemble the human situation and therefore better
serve translational approaches. However, in these animals the
symptoms develop only after months with much broader and
milder phenotypes. For gene effect studies like ours, the situation
is further complicated by the mosaic-like inactivation of Mecp2
on the unaffected chromosome. With an early onset of symptoms
and lethality starting at P45–50, the MeCP2-deficient male mice
might compare better to the early development of symptoms in
humans. Most importantly and from an experimental point of
view, the complete lack of MeCP2 in this genotype is better suited
for the analysis of regulatory effects on the serotonergic system.
We used RT-qPCR to determine the mRNA levels of all
16 components of the murine serotonergic system. In the
brainstem, five genes were differentially regulated between WT
and Mecp2−/y mice. The mRNA level of Htr2c and Tph2 were
reduced, whereas the mRNA levels for Htr1d, Htr5b and Ddc were
increased. In hippocampus, only two genes showed differential
expression, with Slc6a4 being down- and Ddc being up-regulated
in Mecp2−/y mice. The down-regulation of two genes seems
strange as MeCP2 mainly acts as a transcriptional suppressor
(Nan et al., 1997), which absence should lead to an increase
of target gene expression. However, there have been reports of
MeCP2 also acting as a transcriptional activator (Chahrour et al.,
2008). The observed differential expression indicates that the
Mecp2-dependent (de-) regulation of genes of the serotonergic
system is region-specific and suggests different methylation
patterns of these genes, since MeCP2 controls gene activity
in response to DNA methylation (Nan et al., 1997; Chahrour
et al., 2008) and different DNA methylation patterns were
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FIGURE 5 | Molecular analysis of 5-ht5b. (A) Specificity control of the antibody used in (B) and Figure 6. N1E-115 neuroblastoma cells were transfected with an
plasmid coding for 5-ht5b-eGFP and were counterstained with DAPI (blue) and with the antibody generated against the C-terminus of 5-ht5b. The antibody was
visualized with an atto647-coupled secondary antibody (red, Sigma–Aldrich, Cat. No. 40839). Only cells transfected with 5-ht5b-eGFP show reactivity with the
antibody. (B) Immuno-blots of N1E-115 neuroblastoma cells transfected with expression constructs for unlabeled full-length or truncated 5-ht5b (Htr5b-tr) receptor
(I – III) and of Mecp2−/y mouse brainstem lysates (IV, V). While no signal is detectable in mock-transfected cells (I), a signal at about 40 kDa corresponding to the full
length protein is detected in transfected cells (II) and murine tissue (IV). Both in cells (II) and murine tissue (IV), an additional signal is visible at about 22.5 kDa. Such a
signal corresponds to a theoretical truncated 5-ht5b receptor (see B) and can be reproduced in cells transfected with a truncated expression construct (III). Full
length and truncated signal disappear in murine tissue if the antibody is pre-incubated with the antigen used for immunization (V). (C) Schematic representation of
the Htr5b gene with exon-intron structure and the 5-ht5b protein with transmembrane domains. In human, the coding sequence is disrupted by insertion and
nonsense mutations (marked by X). However, translation from the second ATG might produce a truncated protein of 197 amino acids with a predicted relative
molecular mass of 22.5 kDa, corresponding with the smaller signal in Western blot analyses. The peptide used for antibody generation is indicated.
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FIGURE 6 | Subcellular localization of 5-ht5b. Intracellular localization of 5-ht5b receptor (red) counterstained against various compartment markers (green) in
N1E neuroblastoma cells: (A) endoplasmic reticulum (ER recognition sequence of calreticulin), (B) cis-golgi network (GM130), (C) plasma membrane (GAP-43),
(D) endosomes (rab5), (E) trans-golgi network (TGN38), (F) lysosomes (LysoTracker) (G) mitochondria (mitochondria recognition sequence of cytochrome
C-oxidase), and (H) peroxisomes (Pex16). Scale bars as indicated.
FIGURE 7 | Signaling mechanisms of intracellular 5-ht5b. (A,B) Representative electron microscopic micrograph of a series of tissue sections of the medullary
brainstem (n = 3 biological replicates) revealed the incorporation of the receptor into organelle membranes. The antibody used was directed against the C terminus,
which faces the cytoplasmic site. Scale bars, 500 nm in (A) and 50 nm in (B). ER, endoplasmic reticulum; Lys, lysosome; Mito, mitochondrion; TGN, trans-Golgi
network. (C) Suggested organization of the truncated receptor in the membrane of endosomes. The G-protein binding site is accessible from the cytoplasm and the
truncation causes a constitutive activity. (D) In co-transfected N1E cells, a GTPγS-assay shows binding of GTPγS to 5-ht5b in absence or in presence of Gα i3 or
Gαs, respectively (n = 3; Asterisks indicate significance, ∗∗∗p < 0.001; one-way ANOVA). Co-expression of 5-ht5b receptor (red) together with inhibitory Gα i3-protein
(blue), produces a faint but visible membrane localization of 5-ht5b, which is absent when 5-ht5b is expressed alone (scale bar = 10 µm).
reported for other MeCP2-controlled genes (Urdinguio et al.,
2008).
The most striking finding was the extent of Htr5b
dysregulation in the brainstem of Mecp2−/y mice, which
reached up to 75-fold excess at P40 and P50. Interestingly,
Htr5b dysregulation in symptomatic Mecp2−/y mice is not
caused by early developmental up-regulation, but rather by a
failure to down-regulate gene expression at later developmental
stages. Moreover, we found that 5-ht5b localizes to intracellular
organelles and interacts with Gαi proteins. The strongest
co-localization of 5-ht5b was with markers for the endosome.
This distribution suggests that the receptor does not reach the cell
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membrane, but does get trapped in intermediate compartments.
The abundance and location of 5-ht5b in the brainstem might
have potential effects on the physiology of Mecp2−/y mice.
(i) Being still able to interact with Gi proteins, the mass of
5-ht5b could scavenge G-proteins, thus blocking Gi signaling
for other GPCRs. (ii) If the internalized 5-ht5b receptors are
constitutively active, changes of the intracellular cyclic adenosine
monophosphate (cAMP) concentration would lead to imbalance
of the second messenger cascades of many GPCRs. Indeed, such a
role of internalized receptors is not uncommon (Irannejad et al.,
2013), and constitutively active GPCRs are known for a long
time (Tao, 2008). (iii) Moreover, one has to consider the negative
effect of 5-ht5b on 5-HT1A, which whom it specifically interacts,
resulting in reduction of 5-HT1A surface expression (preliminary
data; not shown).
The serotonergic system, especially in the brainstem, has
been shown to be important for the modulation of breathing
(Schwarzacher et al., 2002; Manzke et al., 2010; Niebert et al.,
2011). The observed down-regulation of Htr2c might, therefore,
contribute to the breathing phenotype seen in Mecp2−/y mice.
Interestingly, Htr2c knock-out mice have also respiratory arrests
with subsequent death following seizures (Tecott et al., 1995).
Moreover, the Lmx1bf/f/p mouse strain, which is lacking nearly
all serotonergic neurons displayed severe apnea, hypoventilation
and reduced hypercapnic response (Hodges et al., 2009).
Although the ultimate cause of the low serotonin levels
in RTT patients remains unknown (Mokler et al., 1998), the
three genes Slc6a4, Ddc and Tph2 could be responsible for this
alteration. The tryptophan hydroxylase 2 (Tph2) is the rate-
limiting enzyme in the synthesis of serotonin (Kuhar et al.,
1999) and a downregulation of Tph2 is in accordance with
low brain serotonin levels. Indeed, a reduced Tph2 expression
has been found in MecP2-deficent mice before (Samaco et al.,
2009). These results are certainly in accordance with low brain
serotonin levels. Nevertheless, the question remains whether
reduced Tph2 expression alone can explain reduced 5HT levels.
MeCP2 was shown to greatly affect brain-derived neurotrophic
factor (BDNF) (Li and Pozzo-Miller, 2014), which in turn is a
neurotrophic factor for serotonergic neurons (Paterson et al.,
2005). In this regard, restoring BDNF function in a mouse model
of RTT had beneficial effects (Ogier et al., 2007). However, the
up-regulation of Htr1d might also be a factor in the reduction
of 5HT. 5-HT1DR was found as an auto-receptor on brainstem
neurons, reducing their activity when activated by binding of
serotonin. Htr1d up-regulation in the brainstem could therefore
auto-inhibit the release of serotonin and thus contribute to low
brain serotonin levels reported previously (Mokler et al., 1998).
We cannot exclude that the observed changes of Ddc and
Slc6a4 are mainly the result of a compensatory mechanism
to counteract the dysregulation discussed above. An increase
of dopa-decarboxylase (encoded by Ddc) should, although not
the rate-limiting enzyme in 5HT synthesis (Kuhar et al., 1999;
Berry, 2004) increase serotonin levels. Similarly, a serotonin
transporter (5-HTT; Slc6a4) down-regulation will impair the re-
uptake of serotonin from the synaptic cleft and this increases
the extracellular levels. Nevertheless, a direct control of Ddc
expression by MeCP2 is possible, as Ddc shows the same direction
of dysregulation in brainstem and hippocampus.
Although Ddc is part of the serotonergic system, its
contribution to the RTT phenotype must also be discussed with
respect to its role in the dopaminergic system. Several groups
reported decreased levels of dopamine in the brain (Jellinger,
2003) and dopamine in the basal ganglia is important for
the execution of coordinated and smooth movement, which is
disturbed in Mecp2−/y mice evidenced by hind limb clasping. As
Ddc is also not the rate-limiting enzyme for dopamine synthesis,
its upregulation here might again be compensatory.
In this regard, our results fit well with the established RTT
pathology. The dysregulation of Tph2 and Htr1d might directly
contribute to low serotonin levels, while the dysregulation of
Slc6a4 and Ddc are, however, likely compensatory.
Taken together, our data points to the complex dysregulation
of the serotonergic system at different levels, which can
contribute to the functional dysregulation in the brain of
MeCP2-deficient mice. This complexity is reflected by the fact
that different strategies of pharmacotherapy seem to improve
symptoms in RTT, although targeting opposing signaling
pathways (reduction of cAMP via 5-HT1A; Abdala et al., 2010)
or (elevation of cAMP via 5-HT7; De Filippis et al., 2014, 2015).
Thus, it appears to be necessary to improve our knowledge
of cell-type specific expression and regulation of serotonin-
dependent GPCRs, not only in our mouse models but, of course,
also in humans, to finally develop effective pharmacological
tools.
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